APDI, Inc. (Alzheimer’s, Parkinson’s, Dementia Impaired)

A Smarter Investment in a Volatile Market

In today’s unstable economic climate, investors are searching for more than just returns—they’re seeking resilience, innovation, and real-world impact. With stock market swings and bond market uncertainty, way too many in AI, and a bubble burst will happen in AI. One sector stands out: neuro-nutraceuticals. The brain health market is experiencing explosive demand, fueled by an aging population and the lack of practical solutions.

APDI, Inc. is not just another supplement company—we’re the breakthrough.

Our flagship product, My Brain Restore™, is a next-generation nutraceutical inspired by a 2025 Japanese university study that showed complete reversal of Parkinson’s, Alzheimer’s, and Lewy Body Dementia symptoms in 100% of the mice tested. Even healthy control mice showed a 20% improvement in cognitive performance. Results like this are virtually unheard of in any preclinical study.

And this is not theoretical—our founder, who battles Parkinson’s and early Alzheimer’s, created and personally uses this formulation. Since January 2025, he’s improved using My Brain Restore™ from Stage 3 Parkinson’s to Stage 1, and ran in the June 1, 2025, Michael J. Fox Foundation marathon. These are tangible, human results.  Our 2026 Book will be on Amazon in January 2026.

 “Our core ingredient is unlike anything currently available, this isn’t a recycled supplement or another trendy extract. It’s a completely reengineered compound, never before used for neurological conditions, and processed with a proprietary method that unlocks its full potential for the first time.” That’s our edge, and it’s unmatchable.”

What Makes This an Exceptional Investment?

• Massive market potential in the $160+ billion supplement and brain health space

• First-mover advantage with a proprietary, patentable product

• Personalized origin with real-world results from the founder himself

• Zero direct competition for our specific formulation and method

• FDA interest rising in allowing broader nutraceutical claims

• Flexible business model: direct-to-consumer, subscription-based, Amazon/Walmart expansion

• Clear exit strategy: scale and exit or dominate the market independently

We’re currently raising $1.5 million in equity at 10% to expand production, scale our operations, and fund clinical validation. Long-term, the right partnership or acquisition could offer massive ROI, especially as the big supplement and pharmaceutical players eye this exploding niche.

For investors seeking participation beyond individual accreditation limits, one viable structure is forming an LLC whose sole purpose is to invest in our company. Under U.S. rules, that LLC would be treated as a single investor, even if it has multiple partners. Companies like ours are limited to 35 accredited investors.

Our current offer is $1.5 million for a 10% equity stake.  However, this can be broken down into different groups investing different amounts to reach the goal or the first round.  In my previous career in the computer industry, I successfully helped raise $3 million and $5 million for the companies I worked with. I’ve worked with excellent investors, and a few painful ones, so we are understandably careful. Above all, we will not compromise product integrity.  

Bottom Line

My Brain Restore™ is a nutraceutical with nootropic benefits, sold as a supplement, but positioned like a therapeutic. It offers neurological repair, not just support, based on science, lived experience, and an unmet need that touches tens of millions of lives.

APDI, Inc. It was formed as a Class C corporation in Delaware.

MY BRAIN RESTORE^TM , ULTRA CHILL MILLED^TM, and Supports the Glymphatic system^TM are filed with the US Patent and Trademark Office along with other trademarks owned by APDI, Inc.

We have now implemented international shipping on our website. While Amazon currently limits us to U.S. sales only, we are in the process of activating additional components to support global fulfillment. We are already shipping to Canada and parts of Europe, and we have a growing demand from Australia and other regions. 

At the same time, I am in discussions with the Michael J. Fox Foundation, which has invited me to serve as a spokesperson during congressional meetings in Washington, D.C. I am currently the sixth-most-requested podcast guest on PodMatch and am booked through June 2026. My upcoming book will be released shortly, with both PDF and eBook versions also planned for Amazon.

The international interest is very real. However, our distribution approach is intentional and selective. We are open to distributors only if they also become investors, whether through equity, a structured loan, or a long-term financial position. In other words, distributors must have meaningful “skin in the game.” Any such partner would also be required to sign nondisclosure and non-compete agreements.

We are a Class C Delaware corporation, which provides flexibility for future public offerings, partnerships, or acquisition opportunities. That said, nothing will ever be done that compromises product quality. I personally consume the identical batches for my Parkinson’s and Alzheimer’s that are shipped worldwide.

I have been using My Brain Restore™ for over a year, though we officially launched it in June 2025. I have experienced my strongest results to date. Despite carrying the APOE4 gene associated with Alzheimer’s risk, I am now cognitively normal. With Parkinson’s, I have not tripped or fallen in over six months, and recently climbed a 20-foot ladder to clean gutters (much to my wife’s concern).  And so far, I am the only person I know who has increased the beta-amyloid ratio in my blood by 10% by taking my brain restore.  My doctor said this was impossible, and none of my doctors would reorder the test. I finally got an online doctor to do it, and even she was amazed that it moved the bar, which Google itself says is impossible.  This explains why the mice got better and why it works on a section of the brain that was so recently discovered that most neurologists don’t even know what it is. 

We’ve also learned that several of our customers are physicians, often identifiable by the “Dr.” prefix in their order information. Two physicians who used the product reported improvements in strength and balance as early observations. Tremors, as expected, appear to take much longer to improve and may require extended use. Another doctor made a meaningful and emotional observation: she was able to let go of her partner’s hand while walking down a trail and, for the first time, walk it by herself without losing her balance.   Personally, I do not intend to stop taking the product, since it’s possible, as with blood pressure medicine or insulin, that when you stop taking it, everything comes back.  From an investor standpoint, this is an Evergreen product subscription-based, and as people see themselves getting better, it is highly unlikely that they will cut off their subscriptions.

There is also a clear opportunity in nursing homes and assisted-living facilities, where Parkinson’s, Alzheimer’s, and Lewy body dementia are highly prevalent. Adoption at the facility level, approved by patients or family members, could meaningfully improve quality of life and potentially reduce caregiver strain and overburdened nursing staff.  Our product is a supplement and therefore requires new FDA approval only FDA wording.  Our product is not banned by any country.

In the US, repurposed cancer drugs for neurological diseases are not widely adopted due to costs exceeding $100,000 annually, with total treatment expenses approaching $250,000 when MRIs and infusions are included. This further limits options and underscores the importance of accessible alternatives.

For investors seeking participation beyond individual accreditation limits, one viable structure is forming an LLC whose sole purpose is to invest in our company. Under U.S. rules, that LLC would be treated as a single investor, even if it has multiple partners. Companies like ours are limited to 35 accredited investors.

Our current offer is $1.5 million for a 10% equity stake.  However, this can be broken down into different groups investing different amounts to reach the goal or the first round.  In my previous career in the computer industry, I successfully helped raise $3 million and $5 million for the companies I worked with. I’ve worked with excellent investors, and a few painful ones, so we are understandably careful. Above all, we will not compromise product integrity.

This is something I take every day, and it is the same product we ship worldwide.  And its quality will always stay that way.

If this aligns with your interests, I will welcome a deeper conversation.

Sincerely,
Mark Burnett

This is more than an investment—it’s a legacy.
Let’s talk. Call Mark at 202-536-5000 or email Mark@MyBrainRestore.com.